- Conditions
- COPD Acute Exacerbation
- Interventions
- Rademikibart in prefilled syringe, Matching placebo in prefilled syringe
- Combination Product · Drug
- Lead sponsor
- Connect Biopharm LLC
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 159 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Palo Alto, California • Valencia, California + 17 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 97–105
of 105
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Chronic Obstructive Pulmonary Disease, COPD Exacerbation, Airflow Obstruction
- Interventions
- High Flow Nasal Cannula
- Device
- Lead sponsor
- Tufts Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Not listed
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2021
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- guideline treatment recommendations
- Behavioral
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- Not listed
- Enrollment
- 717 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 2
- States / cities
- Boise, Idaho • Seattle, Washington
- Conditions
- COPD, COPD Exacerbation
- Interventions
- Beclomethasone Dipropionate, Glycopyrronium Bromide, Formoterol Fumarate
- Drug
- Lead sponsor
- Chiesi Farmaceutici S.p.A.
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 3,406 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 276
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Foley, Alabama + 178 more
- Conditions
- Pulmonary Disease, Chronic Obstructive, Airway Disease, COPD Exacerbation, Pollution; Exposure, Pollution Related Respiratory Disorder
- Interventions
- Ozone exposure
- Other
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 45 Years to 75 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2030
- U.S. locations
- 3
- States / cities
- San Francisco, California
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Zileuton, Placebo
- Drug
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 45 Years and older
- Enrollment
- 119 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Francisco, California + 8 more
- Conditions
- COPD Exacerbation Acute
- Interventions
- CUVITRU - Ig subcutaneous human 20%, Standard Medical Therapy
- Biological · Other
- Lead sponsor
- Rochester General Hospital
- Other
- Eligibility
- 18 Years to 82 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 3
- States / cities
- Rochester, New York
- Conditions
- COPD Exacerbation Acute
- Interventions
- AIRVO 2, the new asymmetric nasal cannula
- Device
- Lead sponsor
- Temple University
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania